SynAct Pharma (Sweden) Performance
| SYNACT Stock | 18.62 0.12 0.64% |
The entity has a beta of 0.37, which indicates possible diversification benefits within a given portfolio. As returns on the market increase, SynAct Pharma's returns are expected to increase less than the market. However, during the bear market, the loss of holding SynAct Pharma is expected to be smaller as well. At this point, SynAct Pharma AB has a negative expected return of -0.17%. Please make sure to validate SynAct Pharma's accumulation distribution, and the relationship between the potential upside and day median price , to decide if SynAct Pharma AB performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days SynAct Pharma AB has generated negative risk-adjusted returns adding no value to investors with long positions. Despite latest weak performance, the Stock's basic indicators remain strong and the current disturbance on Wall Street may also be a sign of long term gains for the company investors. ...more
| Begin Period Cash Flow | 14.5 M | |
| Total Cashflows From Investing Activities | -6000.00 |
SynAct |
SynAct Pharma Relative Risk vs. Return Landscape
If you would invest 2,110 in SynAct Pharma AB on November 16, 2025 and sell it today you would lose (248.00) from holding SynAct Pharma AB or give up 11.75% of portfolio value over 90 days. SynAct Pharma AB is generating negative expected returns and assumes 2.763% volatility on return distribution over the 90 days horizon. Simply put, 24% of stocks are less volatile than SynAct, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
SynAct Pharma Target Price Odds to finish over Current Price
The tendency of SynAct Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 18.62 | 90 days | 18.62 | close to 99 |
Based on a normal probability distribution, the odds of SynAct Pharma to move above the current price in 90 days from now is close to 99 (This SynAct Pharma AB probability density function shows the probability of SynAct Stock to fall within a particular range of prices over 90 days) .
SynAct Pharma Price Density |
| Price |
Predictive Modules for SynAct Pharma
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as SynAct Pharma AB. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of SynAct Pharma's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
SynAct Pharma Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. SynAct Pharma is not an exception. The market had few large corrections towards the SynAct Pharma's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold SynAct Pharma AB, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of SynAct Pharma within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.23 | |
β | Beta against Dow Jones | 0.37 | |
σ | Overall volatility | 1.12 | |
Ir | Information ratio | -0.1 |
SynAct Pharma Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of SynAct Pharma for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for SynAct Pharma AB can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| SynAct Pharma AB generated a negative expected return over the last 90 days | |
| SynAct Pharma AB has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (76.7 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| SynAct Pharma generates negative cash flow from operations | |
| About 37.0% of the company outstanding shares are owned by corporate insiders |
SynAct Pharma Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of SynAct Stock often depends not only on the future outlook of the current and potential SynAct Pharma's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. SynAct Pharma's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 26 M | |
| Cash And Short Term Investments | 24 M |
SynAct Pharma Fundamentals Growth
SynAct Stock prices reflect investors' perceptions of the future prospects and financial health of SynAct Pharma, and SynAct Pharma fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on SynAct Stock performance.
| Return On Equity | -1.49 | |||
| Return On Asset | -0.81 | |||
| Current Valuation | 2.08 B | |||
| Shares Outstanding | 31.82 M | |||
| Price To Book | 26.57 X | |||
| EBITDA | (76.62 M) | |||
| Book Value Per Share | 2.82 X | |||
| Cash Flow From Operations | (65 M) | |||
| Total Asset | 38.37 M | |||
About SynAct Pharma Performance
By analyzing SynAct Pharma's fundamental ratios, stakeholders can gain valuable insights into SynAct Pharma's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if SynAct Pharma has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if SynAct Pharma has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Things to note about SynAct Pharma AB performance evaluation
Checking the ongoing alerts about SynAct Pharma for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for SynAct Pharma AB help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| SynAct Pharma AB generated a negative expected return over the last 90 days | |
| SynAct Pharma AB has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (76.7 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| SynAct Pharma generates negative cash flow from operations | |
| About 37.0% of the company outstanding shares are owned by corporate insiders |
- Analyzing SynAct Pharma's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether SynAct Pharma's stock is overvalued or undervalued compared to its peers.
- Examining SynAct Pharma's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating SynAct Pharma's management team can have a significant impact on its success or failure. Reviewing the track record and experience of SynAct Pharma's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of SynAct Pharma's stock. These opinions can provide insight into SynAct Pharma's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for SynAct Stock analysis
When running SynAct Pharma's price analysis, check to measure SynAct Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy SynAct Pharma is operating at the current time. Most of SynAct Pharma's value examination focuses on studying past and present price action to predict the probability of SynAct Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move SynAct Pharma's price. Additionally, you may evaluate how the addition of SynAct Pharma to your portfolios can decrease your overall portfolio volatility.
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios |